Brief: Clover Biopharmaceuticals Says Positive Phase 2/3 Results In Adolescents For Clover''s Covid-19 Vaccine
25/08/2022 11:38
Aug 25 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* POSITIVE PHASE 2/3 RESULTS IN ADOLESCENTS FOR CLOVER''S
COVID-19
VACCINE
* STUDY SUCCESSFULLY MET PRIMARY ENDPOINT
* PLANS TO SUBMIT DATA AND SEEK LICENSURE IN ADOLESCENTS
FROM
GLOBAL REGULATORY AUTHORITIES
Source text for Eikon: ID:nHKSc0CJhk
Further company coverage: 2197.HK
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune